lenvatinib and pembrolizumab


( Last Updated : November 29, 2021)
Generic Name:
lenvatinib and pembrolizumab
Project Status:
Active
Therapeutic Area:
advanced or metastatic renal cell carcinoma
Manufacturer:
Eisai Limited
Call for patient/clinician input open:
Brand Name:
Lenvima and Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0268-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Lenvatinib, in combination with pembrolizumab, for the treatment of adult patients with advanced or metastatic RCC with no prior systemic therapy for metastatic RCC.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Lenvatinib, in combination with pembrolizumab, for the treatment of adult patients with advanced or metastatic RCC with no prior systemic therapy for metastatic RCC.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones

Call for patient/clinician input open October 18, 2021
Call for patient/clinician input closed December 09, 2021
Submission received November 15, 2021
Submission accepted  
Review initiated November 30, 2021
Draft CADTH review report(s) provided to sponsor for comment February 18, 2022
Deadline for sponsors comments March 02, 2022
CADTH review report(s) and responses to comments provided to sponsor April 01, 2022
Expert committee meeting (initial) April 13, 2022
Draft recommendation issued to sponsor April 26, 2022
To
April 28, 2022
Draft recommendation posted for stakeholder feedback May 05, 2022
End of feedback period May 19, 2022